Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

52 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Bax inhibitor-1 protects from nonalcoholic steatohepatitis by limiting inositol-requiring enzyme 1 alpha signaling in mice.
Lebeaupin C, Vallée D, Rousseau D, Patouraux S, Bonnafous S, Adam G, Luciano F, Luci C, Anty R, Iannelli A, Marchetti S, Kroemer G, Lacas-Gervais S, Tran A, Gual P, Bailly-Maitre B. Lebeaupin C, et al. Among authors: vallee d. Hepatology. 2018 Aug;68(2):515-532. doi: 10.1002/hep.29847. Epub 2018 May 18. Hepatology. 2018. PMID: 29457838
BAX inhibitor-1: between stress and survival.
Lebeaupin C, Blanc M, Vallée D, Keller H, Bailly-Maitre B. Lebeaupin C, et al. Among authors: vallee d. FEBS J. 2020 May;287(9):1722-1736. doi: 10.1111/febs.15179. Epub 2020 Jan 8. FEBS J. 2020. PMID: 31841271 Free PMC article. Review.
Long-term cellular immunity of vaccines for Zaire Ebola Virus Diseases.
Wiedemann A, Lhomme E, Huchon M, Foucat E, Bérerd-Camara M, Guillaumat L, Yaradouno M, Tambalou J, Rodrigues C, Ribeiro A, Béavogui AH, Lacabaratz C, Thiébaut R, Richert L, Lévy Y; Prevac study team. Wiedemann A, et al. Nat Commun. 2024 Sep 3;15(1):7666. doi: 10.1038/s41467-024-51453-z. Nat Commun. 2024. PMID: 39227399 Free PMC article. Clinical Trial.
Early trajectories of virological and immunological biomarkers and clinical outcomes in patients admitted to hospital for COVID-19: an international, prospective cohort study.
Jensen TO, Murray TA, Grandits GA, Jain MK, Grund B, Shaw-Saliba K, Matthay MA, Abassi M, Ardelt M, Baker JV, Chen P, Dewar RL, Goodman AL, Hatlen TJ, Highbarger HC, Holodniy M, Lallemand P, Laverdure S, Leshnower BG, Looney D, Moschopoulos CD, Mugerwa H, Murray DD, Mylonakis E, Nagy-Agren S, Rehman MT, Rupert A, Stevens R, Turville S, Weintrob A, Wick K, Lundgren J, Ko ER; ACTIV-3/TICO Study Group. Jensen TO, et al. Lancet Microbe. 2024 Jun;5(6):e559-e569. doi: 10.1016/S2666-5247(24)00015-6. Epub 2024 May 27. Lancet Microbe. 2024. PMID: 38815595 Free article. Clinical Trial.
Viral and Host Factors Are Associated With Mortality in Hospitalized Patients With COVID-19.
Aggarwal NR, Nordwall J, Braun DL, Chung L, Coslet J, Der T, Eriobu N, Ginde AA, Hayanga AJ, Highbarger H, Holodniy M, Horcajada JP, Jain MK, Kim K, Laverdure S, Lundgren J, Natarajan V, Nguyen HH, Pett SL, Phillips A, Poulakou G, Price DA, Robinson P, Rogers AJ, Sandkovsky U, Shaw-Saliba K, Sturek JM, Trautner BW, Waters M, Reilly C; ACTIV-3/TICO Study Group. Aggarwal NR, et al. Clin Infect Dis. 2024 Jun 14;78(6):1490-1503. doi: 10.1093/cid/ciad780. Clin Infect Dis. 2024. PMID: 38376212 Clinical Trial.
Immunogenicity and Vaccine Shedding After 1 or 2 Doses of rVSVΔG-ZEBOV-GP Ebola Vaccine (ERVEBO®): Results From a Phase 2, Randomized, Placebo-controlled Trial in Children and Adults.
Lee AW, Liu K, Lhomme E, Blie J, McCullough J, Onorato MT, Connor L, Simon JK, Dubey S, VanRheenen S, Deutsch J, Owens A, Morgan A, Welebob C, Hyatt D, Nair S, Hamzé B, Guindo O, Sow SO, Beavogui AH, Leigh B, Samai M, Akoo P, Serry-Bangura A, Fleck S, Secka F, Lowe B, Watson-Jones D, Roy C, Hensley LE, Kieh M, Coller BG; PREVAC Study Team. Lee AW, et al. Clin Infect Dis. 2024 Apr 10;78(4):870-879. doi: 10.1093/cid/ciad693. Clin Infect Dis. 2024. PMID: 37967326 Free PMC article. Clinical Trial.
Effect of Neutralizing Monoclonal Antibody Treatment on Early Trajectories of Virologic and Immunologic Biomarkers in Patients Hospitalized With COVID-19.
Jensen TO, Grandits GA, Jain MK, Murray TA, Grund B, Shaw-Saliba K, Matthay MA, Abassi M, Ardelt M, Baker JV, Chen P, Dewar RL, Goodman AL, Hatlen TJ, Highbarger HC, Holodniy M, Lallemand P, Laverdure S, Leshnower BG, Looney D, Moschopoulos CD, Mugerwa H, Murray DD, Mylonakis E, Nagy-Agren S, Rehman MT, Rupert A, Stevens RA, Turville S, Weintrob A, Wick K, Lundgren J, Ko ER; ACTIV-3/TICO Study Group. Jensen TO, et al. J Infect Dis. 2024 Mar 14;229(3):671-679. doi: 10.1093/infdis/jiad446. J Infect Dis. 2024. PMID: 37948759 Free PMC article. Clinical Trial.
52 results